Skip to main content

Generics

  • Mallinckrodt donates drug deactivation pouches in 7 states
    CHESTERFIELD, U.K. — Mallinckrodt Pharmaceuticals announced Thursday that it would be making it easier for people in the Midwest and in central Appalachia to dispose of their leftover prescription medications. The company will be making 160,000 drug deactivation pouches to families at nearly 800 Walmart stores in Indiana, Kentucky, Ohio, Pennsylvania, South Carolina, Tennessee and West Virginia.
     

  • Gilead honors Camber parent company Hetero Drugs
    PISCATAWAY, N.J. — Camber Pharmaceuticals announced Wednesday that its parent company, Hetero Drugs, has been recognized by Gilead Sciences for its work providing access to hepatitis C drugs for patients worldwide. Hetero markets sofosbuvir  as Sofovir and ledipasvir-sofosbuvir as Ledifos in India and will eventually reach some 91 countries. The two drugs are better known in the United States and as Sovaldi and Harvoni. 
     
    In India, an estimated 12 million to 18 million patients are infected with hepatitis C. 

  • QuintilesIMS Institute report: Generics brought $227 billion in 2015 savings
    WASHINGTON —QuintilesIMS on Wednesday released its 2016 Generic Drug Savings and Access in the United States Report, which it compiled on behalf of the Generic Pharmaceutical Association (GPhA). 
     

  • Amneal launches first Vagifem generic
    BRIDGEWATER, N.J. — Amneal Pharmaceuticals on Tuesday announced the launch of its Yuvafem (estradiol vaginal inserts 10 mcg), the first generic of Vagifem. The drug delivers the same low dose of vaginal estrogen as Vagifem, and is packaged in 8- and 18-count sizes. 
     

  • Pfizer announces availability of Inflectra, its Remicade biosimilar
    NEW YORK — Pfizer on Tuesday announced that it will begin shipping its Inflectra (infliximab-dyyb), a biosimilar of Remicade (infliximab), to U.S. wholesalers starting at the end of November. 
     
    Inflectra will be the second biosimilar available in the United States, and the first biosimilar monoclonal antibody. Pfizer will introduce Inflectra at a 15% discount to the current wholesaler acquisition cost of Remicade.
     

  • Upsher-Smith acquires 20 generics from Sandoz
    MAPLE GROVE, Minn. — Upsher-Smith Laboratories announced Tuesday that it had acquired 20 U.S. generic products from Sandoz for an upfront cash payment and additional payments contingent on product sales. The terms of the transaction were not disclosed. 
     

  • Report: Lannett shares fall after FDA withdraws Concerta generic approval

  • Naloxone access, community efforts work to curb opioid abuse

    Drug overdoses have become the leading cause of accidental death in the United States, with 47,055 people dying in 2014 as a result of lethal drug overdoses — 18,893 of which were related to prescription pain relievers. The epidemic has drawn the attention of everyone from President Barack Obama to local first responders, all of whom have pointed to the drug naloxone as one of the critical first lines of defense in saving the lives of thousands from accidental overdose. Naloxone can reverse the effects of an overdose, but until recently it could only be accessed by prescription.

X
This ad will auto-close in 10 seconds